Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $17.1667.
Several brokerages recently weighed in on KPTI. Robert W. Baird decreased their price objective on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, March 25th. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, June 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, July 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Thursday, June 18th.
Read Our Latest Stock Report on KPTI
Institutional Inflows and Outflows
Karyopharm Therapeutics Trading Up 1.4%
Shares of NASDAQ KPTI opened at $9.51 on Friday. The stock has a fifty day simple moving average of $9.18 and a two-hundred day simple moving average of $8.25. Karyopharm Therapeutics has a 1-year low of $3.65 and a 1-year high of $10.99. The firm has a market cap of $215.50 million, a price-to-earnings ratio of -0.63 and a beta of 0.80.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.21. The firm had revenue of $35.07 million during the quarter, compared to analysts’ expectations of $31.40 million. Analysts forecast that Karyopharm Therapeutics will post -3.24 EPS for the current year.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.
Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.
Featured Articles
- Five stocks we like better than Karyopharm Therapeutics
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
